Browsing by Author "Millot, Frederic"
Now showing 1 - 5 of 5
- Results Per Page
- Sort Options
Publication Characteristics, treatment and outcome of 15 to 18 years-old adolescents with Chronic Myeloid Leukemia (CML): The experience of the International Registry of Childhood CML (I-CML-Ped Study)(American Society of Hematology, 2021-11-23) Froment, Morgane; Suttorp, Meinolf; Ragot, Stephanie; Deutsch, Helene; Goyeau, Violaine; De Moerloose, Barbara; Brandalise, Silvia Regina; Borisevich, Marina; Sedlacek, Petr; Gunes, Adalet Meral; Lausen, Birgitte; Molines Honrubia, Antonio; Jakovljevic, Gordana; Versluys, Birgitta; Kalwak, Krzysztof; Hraskova, Andrea; Millot, Frederic; MERAL GÜNEŞ, ADALET; Uludağ Üniversitesi/Tıp Fakültesi; EXD-8400-2022Item Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia(Elsevier, 2019-07) Millot, Frederic; Maledon, Natacha; Guilhot, Joelle; Kalwak, Krzysztof; Suttorp, Meinolf; Güneş, Adalet Meral; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Dahili Tıp Bilimleri/Çocuk Sağlığı Ve Hastalıkları Bölümü.; 24072843300Background: Chronic myeloid leukaemia (CML) is very rare in children. The aim of the study is to report the experience within the I-CML-Ped study in children and adolescents presenting at diagnosis with advanced phase disease and to describe their characteristics and outcomes. Methods: Of 479 children and adolescents enrolled in the international registry for childhood chronic myeloid leukaemia (I-CML-Ped Study; www.clinicaltrials.gov NCT01281735), 36 children (7.5%) presented at initial diagnosis with CML in advanced phase according to the European Leukemia Net criteria. Results: Nineteen (4%) patients were diagnosed in accelerated phase (CML-AP), and among the 17 patients (3.5%) diagnosed in blastic phase (CML-BP), 70% presented with lymphoid immunophenotype. Initial treatment of CML-AP/CML-BP consisted of tyrosine kinase inhibitors (TKIs) with or without chemotherapy, leading to complete haematologic response in 33 of 36 (92%) patients. Seventeen patients proceeded to haematopoietic stem cell transplantation. At the last follow-up, 18 of 19 patients with de novo CML-AP are alive in at least major molecular response (MMR) (n = 16), in progression (n = 1) or in molecular relapse (n = 1) and 13 of 17 patients with de novo CML-BP are alive in at least MMR. Five-year overall survival rates are 94% (95% confidence interval [CI]: 66%-99%) and 74% (95% CI: 44%-89%) for patients diagnosed in CML-AP and CML-BP, respectively. Conclusion: Children with advanced phase at diagnosis of CML seem to have a better survival rate than that reported for advanced phases evolving under TKI treatment.Item Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients(Wiley, 2018-12) Suttorp, Meinolf; Metzler, Markus; Millot, Frederic; Shimada, Hiroyuki; Bansal, Deepak; Kalwak, Krzysztof; Sedlacek, Petr; Baruchel, Andre; Biondi, Andrea; Hijiya, Nobuko; Schultz, Kirk R.; Schrappe, Martin; Güneş, Adalet Meral; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Kliniği.; EXD-8400-2022; 24072843300Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia.Item Prognostic discrimination of children and adolescents with chronic myeloid leukemia based on the EUTOS long term survival (ELTS) score(Amer Soc Hematology, 2016-12-02) Millot, Frederic; Guilhot, Joelle; Suttorp, Meinolf; Sedlacek, Petr; De Bont, Evelina S.; Li, Chi Kong; Kalwak, Krzysztof; Lausen, Birgitte; Culic, Srdjana; De Moerloose, Barbara; Biondi, Andrea; Baruchel, Andre; Güneş, Adalet Meral; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı.; EXD-8400-2022Publication Switch to subsequent line of treatment in children and adolescents with chronic myeloid leukemia (CML) treated with imatinib: Experience of the international registry for chronic myeloid leukemia in children and adolescents (I-CML-Ped Study)(Amer Soc Hematology, 2015-12-03) Millot, Frederic; Guilhot, Joelle; Suttorp, Meinolf; Meunier, Anne Sophie; Meral, Güneş Adalet; Sedlacek, Petr; de Bont, Eveline; Li, Chi Kong; Kalwak, Krzysztof; Lausen, Birgitte; Culic, Srdjana; De Moerloose, Barbara; Biondi, Andrea; Baruchel, Andre; MERAL GÜNEŞ, ADALET; Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Anabilim Dalı.; IMO-4290-2023